This product requires more solution for successful reconstitution.

• • Mechanism of Action:
    • Cagrilintide activates both amylin and calcitonin receptors, offering a distinct mechanism of action compared to other weight loss agents like GLP-1 receptor agonists.
    • This dual receptor activity leads to increased satiety (feeling of fullness), reduced food intake, and delayed gastric emptying.
    • Cagrilintide also plays a role in managing blood glucose levels by helping to suppress glucagon, a hormone that raises blood sugar.
    • Its structure is modified from pramlintide, the backbone peptide, with changes to enhance effectiveness, inhibit amyloid fibril formation, and prolong its action.
  • Therapeutic Uses:
    • Cagrilintide is being investigated as a treatment for obesity and type 2 diabetes.
    • It is often studied in combination with semaglutide, a GLP-1 receptor agonist, forming a co-formulation called CagriSema.
    • Early trials suggest it may also offer benefits for liver damage, alcohol-related liver disease, and heart/blood vessel disease.
  • Clinical Trial Results (CagriSema):
    • CagriSema has entered Phase III clinical trials.
    • The REDEFINE 1 trial demonstrated significant weight loss in obese/overweight individuals treated with CagriSema. Over 68 weeks, participants experienced an average weight loss of 20.4%, compared to 3.0% with placebo.
    • The REDEFINE 2 trial in individuals with overweight or obesity and type 2 diabetes also showed substantial weight reduction with CagriSema, nearly 16% in patients adhering to treatment.
    • Clinical trial data indicates CagriSema can also improve blood pressure, waist circumference, lipid levels, and glycemic control.
  • Side Effects:
    • The most common side effects associated with cagrilintide are gastrointestinal, including nausea, constipation, and diarrhea.
    • These side effects are similar to those seen with semaglutide alone and tend to decrease over time.
    • Some patients describe a clear reduction in appetite without the intense nausea sometimes associated with GLP-1 receptor agonists.